Loading
Visugromab is CatalYm's antibody against GDF-15, a tumour-made signal that both blocks immune cells and causes cancer wasting; it is in a phase 3 trial with PD-1 blockade after durable responses in patients whose cancers had stopped responding to checkpoint inhibitors.
CatalYm, a Munich biotech, developed visugromab (CTL-002) after showing that GDF-15 secreted by tumours prevents T cells from entering them. In the GDFATHER trials it produced durable responses with nivolumab in patients with checkpoint-refractory cancers, and the same molecule is being studied for cancer-associated cachexia, since GDF-15 acts on the brainstem to suppress appetite. A phase 3 trial is registered.
Neutralises growth differentiation factor 15, a cytokine many tumours secrete that keeps T cells out of the tumour and drives cachexia; blocking it is meant to restore immune infiltration and reverse weight loss.
1.Visugromab binds its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Visugromab" OR ABSTRACT:"Visugromab" OR TITLE:"CTL-002" OR ABSTRACT:"CTL-002") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Visugromab, not a curated reading list.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.
Shares Immune checkpoint inhibitors and the tag pipeline.